PSYENCE BIOMEDICAL LTD (PBM)
CA74449F1009 - Common Stock
These stocks are moving in today's after hours session
After hours stock analysis on 2024-12-20: top gainers and losers in today's session.
Which stocks are moving before the opening bell on Friday?
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Top movers analysis in the middle of the day on 2024-12-19: top gainers and losers in today's session.
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO),...
Get insights into the top gainers and losers of Tuesday's pre-market session.
Top movers in Tuesday's pre-market session
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
Psyence Biomed obtains exclusive worldwide supply rights to Optimi’s GMP-certified, nature-derived psilocybin for its drug development and...
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Gapping stocks in Monday's session
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session.
Friday's session: gap up and gap down stocks
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.
After hours stock analysis on 2024-12-05: top gainers and losers in today's session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Independent valuation of PsyLabs values Psyence Biomed’s stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and...
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the favorable...
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date...
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results...
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence...
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being ...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin...
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin...
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder,...
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being...
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol...
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company...